Related Experiment Video
Updated: Jun 14, 2026
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Analysis of Local Recurrence After Robotic-Assisted Total Mesorectal Excision (ALRITE): An International,
Ritch T J Geitenbeek1,2, Rauand Duhoky3,4, Thijs A Burghgraef1,2
1Department of Surgery, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Cancers
|March 28, 2025
Summary
Robot-assisted total mesorectal excision (R-TME) shows a low 3-year local recurrence rate of 3.8% in rectal cancer patients. This highlights the oncological safety and benefits of robotic surgery, improving patient outcomes.
Area of Science:
- Surgical Oncology
- Robotic Surgery
- Gastrointestinal Cancer Research
Background:
- Rectal cancer presents significant global health challenges with high morbidity and mortality.
- Local recurrence (LR) after surgery severely impacts patient survival and necessitates further treatment.
- Robot-assisted total mesorectal excision (R-TME) is increasingly adopted, but long-term LR data and predictors are limited.
Purpose of the Study:
- To determine the 3-year LR rate following R-TME for rectal cancer.
- To identify key predictors of LR after R-TME.
- To enhance patient selection and personalize treatment strategies for rectal cancer.
Main Methods:
- Retrospective international multicentre cohort study of 1039 rectal cancer patients undergoing R-TME (2013-2020).
- Minimum 3-year follow-up data analyzed from European tertiary colorectal centers.
- Backward elimination and machine learning models (e.g., eXtreme Gradient Boosting) used to identify LR predictors.
Main Results:
- The 3-year LR rate was 3.8% in the R-TME cohort.
- Significant LR predictors included advanced M-staging, prolonged hospital stay, postoperative ileus/complications, N-staging, resection completeness, and margin distance.
- The eXtreme Gradient Boosting model achieved 77.1% accuracy and 0.76 AUC for LR prediction.
Conclusions:
- R-TME performed in high-volume centers demonstrates low 3-year LR rates, confirming its oncological safety.
- Robotic surgery offers advantages in rectal cancer management, emphasizing surgical precision and patient selection.
- Further investment in robotic training is recommended to optimize long-term patient outcomes.
